Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SF3B3 | Q15393 | 10/20 | 0.68 |
| ▸ | HMGCR | P04035 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748880 | 0.93 | SF3B3 (0.71) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14539614 | 0.92 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12877318 | 0.92 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12877481 | 0.92 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL905749 | 0.92 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30311586 | 0.92 | SF3B3 (0.76) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1505041 | 0.91 | SF3B3 (0.69) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12833633 | 0.91 | SF3B3 (0.69) | SF3B3HMGCRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13503195 | 0.91 | SF3B3 (0.68) | SF3B3HMGCR | |
| SCHEMBL3626331 | 0.91 | SF3B3 (0.68) | SF3B3HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655442-B2 | Efficiently producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes; antitumor agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-02 | — | — | US | claimed |
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MERCIAN CORPORATION (JP) | 2007-07-05 | — | — | US | claimed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | claimed |
| US-7026352-B1 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2006-04-11 | — | — | US | claimed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7655442-B2 | Efficiently producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes; antitumor agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MERCIAN CORPORATION (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MRPL21, ERG28, RPN1 | SF3B3 2845/4885HMGCR 173/4885MEN1 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.